Extended follow-up data from the ADAURA trial show that the disease-free survival benefit with adjuvant osimertinib over placebo continues beyond the 3-year treatment duration in people with EGFR -mutated stage IB–IIIA non-small-cell lung cancer.

Adding the PD-1 inhibitor sintilimab and the bevacizumab biosimilar IBI305 to chemotherapy significantly improves the progression-free survival of people with EGFR -mutated, nonsquamous non-small-cell lung cancer that has progressed after prior EGFR–tyrosine kinase inhibitor therapy, suggests an interim analysis of a Chinese phase 3 trial.

The immunoglobulin G1-based EGFR–MET bispecific antibody has also been approved for this NSCLC indication by the US FDA following positive phase 1 CHRYSALIS trial results for objective response rate and duration.

Here, we present the case of an EGFR-mutated NSCLC patient who underwent a complete response to the anti-programmed cell death 1 (PD-1) agent pembrolizumab upon disease progression on the EGFR-TKI afatinib.

Health-related quality of life is maintained during long-term treatment with adjuvant osimertinib in people with resected, EGFR -mutated non-small-cell lung cancer, research shows.

Adding bevacizumab to osimertinib therapy does not improve progression-free survival for patients with advanced non-small-cell lung cancer harboring an EGFR T790M mutation, phase 2 study data suggest.

CHRYSALIS trial findings suggest that the bispecific monoclonal antibody amivantamab could be combined with the third-generation EGFR–tyrosine kinase inhibitor lazertinib for the treatment of patients with metastatic or unresectable non-small-cell lung cancer with an EGFR exon 19 deletion or L858R mutation.

Treatment-naïve EGFR -mutant non-small-cell lung cancer patients are unlikely to benefit from the addition of cetuximab to afatinib, results suggest.

Chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer and EGFR -activating mutations derive prolonged progression-free survival from the addition of apatinib to gefitinib, phase 3 ACTIVE data show.

Julia Rotow outlines the rationale and preliminary findings of a study of concurrent osimertinib and gefitinib for treatment-naïve EGFR -mutated non-small-cell lung cancer (6:59).

Combining osimertinib with gefitinib has promising efficacy and tolerability in treatment-naïve patients with metastatic EGFR -mutated non-small-cell lung cancer, suggest early data presented at the virtual 2020 ASCO Annual Meeting.

Patients with stage IB–IIIA non-small-cell lung cancer harboring EGFR mutations derive a significant disease-free survival benefit from adjuvant treatment with osimertinib, shows the phase 3 ADAURA trial.

Phase III study results suggest gefitinib in combination with chemotherapy improves outcomes versus gefitinib alone in patients with EGFR -mutated, advanced non-small-cell lung cancer.

Osimertinib and gefitinib plus pemetrexed-based chemotherapy offer the best survival outcomes for patients with advanced EGFR -mutated non-small-cell lung cancer compared with other first-line treatments, shows a network meta-analysis of randomized trials.

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

However, he pointed out that the rates of response and nodal downstaging were lower than expected in both study arms, and added that the treatment effect of erlotinib appeared to be less than that seen in stage IV EGFR -mutated NSCLC.

Patients with advanced non-small-cell cancer with activating EGFR mutations derive a significant overall survival benefit from first-line treatment with dacomitinib relative to gefitinib, the ARCHER 1050 trial shows.

Afatinib was initially approved by the FDA for metastatic NSCLC positive for an EGFR exon 19 deletion or an exon 21 substitution, and then later for patients with metastatic squamous NSCLC that has progressed after platinum-based chemotherapy.